All In Biotech

NDA 018667 · Hospira

Furosemide

Furosemide · Injection · Loop Diuretic

Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

May 28, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

345

66 Phase 3, 33 recruiting

FAERS reports

265,537

219,231 serious, 40,876 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 11, 2026.

FUROSEMIDE INJECTION is a loop diuretic indicated for: The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease ( 1.1 ) Acute pulmonary edema as adjunctive therapy ( 1.2 ) 1.1 Edema Furosemide Injection is indicated in adults and pediatric patients for the treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 1.2 Acute Pulmonary Edema Furosemide Injection is indicated as adjunctive therapy in acute pulmonary edema.

Mechanism: Furosemide inhibits primarily the reabsorption of sodium and chloride not only in the proximal and distal tubules but also in the loop of Henle. The high degree of efficacy is largely due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 1982 Original approval
1 products under this application
  • FUROSEMIDE · FUROSEMIDE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Furosemide" as an intervention, any sponsor and status, largest first.

All 345 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea18,437
  • acute kidney injury16,467
  • fatigue13,248
  • diarrhoea13,195
  • death12,368
  • nausea11,534
  • fall11,003
  • off label use10,842
  • drug ineffective10,424
  • hypotension10,330
  • pneumonia10,172
  • dizziness9,887

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,479
20053,857
20063,623
20073,214
20083,608
20093,997
20104,832
20116,479
20127,274
20137,405
201410,059
201513,254
201616,201
201716,716
201821,192
201923,004
202020,355
202118,734
202216,306
202316,473
202417,411
202516,227
202611,830

Recalls

2 FDA enforcement reports for this application.

  • Feb 26, 2013 · Class II · Terminated

    Lack of Assurance of Sterility: Loose crimp applied to the fliptop vial.

  • Jan 10, 2013 · Class II · Terminated

    Lack of Assurance of Sterility; possible loose crimp applied to fliptop vial

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02).

  • Current · updated Nov 9, 2026

    Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10).

  • Current · updated Nov 9, 2026

    Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27). Other

  • Current · updated Nov 9, 2026

    Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26). Other

  • Current · updated Nov 9, 2026

    Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04).

  • Current · updated Nov 9, 2026

    Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Furosemide* (Furosemide)

2024 spending

$119M

Beneficiaries

5,790,198

23,553,663 claims

Per beneficiary

$21

$0.08 per unit

View as table
YearSpending
2020$147,144,669
2021$140,004,881
2022$139,702,947
2023$144,867,352
2024$118,928,717

Part B: Furosemide (Furosemide) · HCPCS J1940

2024 spending

$30K

Beneficiaries

16,747

27,644 claims

Per beneficiary

$2

2024 ASP limit $0.50 per unit

View as table
YearSpending
2020$50,841
2021$44,701
2022$40,222
2023$37,593
2024$29,817

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,427 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.